

Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman

July 21, 2020

ATTORNEYS

Mathias, Ted

Ropka, PhD, Stacie

PRACTICE AREAS

Biotechnology

Patents

The Center for Biosimilars

On July 21, Axinn partners Ted Mathias and Stacie Ropka participated in a video interview with *The Center for Biosimilars*. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.

[Click here to access the interview.](#)